Twenty-four women were injected with a drug called MVT-602 which targets the kisspeptin system to stimulate reproductive hormones that affect fertility, sexual development and menstruation. The naturally occurring form of kisspeptin, called kisspeptin-54 (KP54), has been researched for a number of years to treat reproductive disorders, but in the new study, MVT-602 induced more potent signaling of the kisspeptin system over a longer period of time than KP54.
The researchers suggest that MVT-602 may be used to effectively treat a range of reproductive conditions that affect fertility, such as polycystic ovary syndrome (PCOS). Because of MVT-602’s much longer duration of action, it can be given less frequently than the naturally occurring form of kisspeptin, whilst still being able to maintain the degree of stimulation of reproductive hormone levels required to restore reproductive health.
The study was published in the Journal of Clinical Investigation.